MoneyWorks4Me

Suven Life Sciences - Quaterly Results

14 May 2026 Evaluate
A minor change in the total revenue was seen in the March 2026 quarter. The total revenue for the quarter stood at Rs. 15.20 millions against Rs. 14.67 millions during year ago period.The Net Loss for the quarter ended March 2026 is Rs. -111.67 millions as compared to Net Loss of Rs. -150.70 millions of corresponding quarter ended March 2025 Operating profit Margin for the quarter ended March 2026 improved to -94.27% as compared to -137.23% of corresponding quarter ended March 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 15.20 14.67 3.61 71.15 66.56 6.90 71.15 66.56 6.90
Other Income 67.78 11.91 469.10 139.10 107.26 29.68 139.10 107.26 29.68
PBIDT -94.27 -137.23 -31.31 -490.91 -412.11 19.12 -490.91 -412.11 19.12
Interest 1.58 0.00 0.00 1.58 0.47 236.17 1.58 0.47 236.17
PBDT -95.85 -137.23 -30.15 -492.49 -412.58 19.37 -492.49 -412.58 19.37
Depreciation 15.82 13.47 17.45 56.14 58.22 -3.57 56.14 58.22 -3.57
PBT -111.67 -150.70 -25.90 -548.63 -470.80 16.53 -548.63 -470.80 16.53
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -111.67 -150.70 -25.90 -548.63 -470.80 16.53 -548.63 -470.80 16.53
Equity 263.72 218.07 20.93 263.72 218.07 20.93 263.72 218.07 20.93
PBIDTM(%) -620.20 -935.45 -33.70 -689.96 -619.16 11.44 -689.96 -619.16 11.44
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..